Real bill currently in Congress c/o HR/119/5160

Stem Cell Therapeutic and Research Reauthorization Act of 2025

Policy area: Health ▲ 45 days since action Sponsor: Christopher H. Smith, NJ-04, R → Congress.gov

Latest action (2026-07-21): Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

What should pass

“AI Consensus Solution”

Read full document →

Stem Cell Therapeutic and Research Reauthorization Act of 2025 – Fiscal Responsibility and Sunset Version

Reauthorize federal funding for the National Cord Blood Inventory and the C.W. Bill Young Cell Transplantation Program to maintain and expand the availability of stem cell therapies for patients with blood cancers and other disorders.

Bipartisan rationale: Democratic priorities honored: continued federal investment in stem cell therapies for life-threatening diseases, maintaining access for underserved populations, and preserving the existing cord blood network. Republican priorities honored: spending cap reduction, sunset provision, prohibition on embryonic stem cell research (consistent with Dickey-Wicker), and enhanced oversight to prevent waste.

Funding: General Treasury revenue (no new tax or fe $50 million per year for 5 yea Sunset 5y Oversight: Health and Human Services Offi Enforcement: Grant conditions requiring complianc

Vote-count path: ~425 House votes: 210 D + 215 R (near-unanimous due to uncontroversial nature and bipartisan fiscal reforms); ~95 Senate votes: 50 D + 45 R (strong support from both sides, with a handful of fiscal conservatives abstaining due to sunset).

→ Article I, Section 8, Clause 1 (Spending for general welfare) → Tenth Amendment (states retain flexibility to operate their own cord blood programs outside the federal grant framework)

← Back to the Republic